ABH Healthcare IPO Day 1: Subscription status, review — here's what you need to know
- ABH Healthcare IPO opened on August 24, 2026, with a total subscription of 0.28x.
- QIB category surged to 3.45x, driving the majority of the day's interest.
- Retail investors subscribed to 0.13x, up from 0.09x earlier in the day.
- The company plans to use ₹17.00 crores for debt repayment and ₹5.00 crores for working capital.
- Key risks include limited operating history since 2021 and high geographic concentration.
*this image is generated using AI for illustrative purposes only.
ABH Healthcare Limited’s initial public offering opened today, recording a total subscription of 0.28x by the end of Day 1 trading. The Qualified Institutional Buyer (QIB) category led the momentum, surging from 0.00x to 3.45x. Retail investors also showed improved interest, subscribing to 0.13x of their quota, up from earlier in the day.
Subscription Status
The IPO picked up pace significantly after midday, driven largely by institutional participation. The following table details the end-of-day subscription multiples:
| Category | Subscription Multiple |
|---|---|
| QIB | 3.45x |
| NII (bHNI) | 0.03x |
| NII (sHNI) | 0.00x |
| Retail | 0.13x |
| Total | 0.28x |
QIBs were the standout performers, jumping +3.45x today. Non-Institutional Investors (bHNI) saw a modest increase to 0.03x, while retail participation rose to 0.13x. The total subscription multiple increased by 460% from the morning snapshot.
Intra-day Timeline
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 11:15 | 0.00x | 0.02x | 0.09x | 0.05x |
| 12:15 | 3.45x | 0.03x | 0.13x | 0.28x |
About the Company
ABH Healthcare Limited operates a 150-bed multi-specialty tertiary care hospital under the "Anil Baghi Hospital" brand in Ferozepur, Punjab. Founded in 2021 and acquiring the business in 2022, the facility originally established in 1985 focuses on Tier 3 city healthcare. Led by U.S.-trained doctors including MD Dr. Kamal Baghi and CEO Dr. Saurabh Baghi, the hospital offers 25 medical specialties such as cardiac sciences and neurology.
Financial Highlights
The company has demonstrated revenue growth over the past three years. Below are the key financial figures for the last three fiscal years:
| Particulars | FY 2024 (₹ crores) | FY 2025 (₹ crores) | FY 2026 (₹ crores) |
|---|---|---|---|
| Revenue from Operations | 41.38 | 49.27 | 52.51 |
| Profit After Tax | 1.66 | 5.35 | 5.64 |
| Total Equity | 6.35 | 11.69 | 17.34 |
Revenue grew from ₹41.38 crores in FY 2024 to ₹52.51 crores in FY 2026. Profitability improved significantly, with PAT rising from ₹1.66 crores to ₹5.64 crores over the same period, reflecting better operational efficiency.
Objects of the Issue
The proceeds from the IPO will be utilized for the following purposes:
- Repayment/prepayment of certain borrowings: ₹17.00 crores
- Funding working capital requirements: ₹5.00 crores
- Funding inorganic growth through unidentified acquisitions and general corporate purposes
Risk Factors
Investors should consider these key risks associated with the issue:
- Limited Operating History as a Company: Incorporated in 2021, making future prospects harder to evaluate.
- Geographic Revenue Concentration Risk: 100% of revenue is derived from a single hospital in Ferozepur.
- High Debt-to-Equity Ratio and Funding Risk: Debt-to-equity ratio stood at 3.20 in Fiscal 2026.
Offer Details
- Price Band: ₹96.00000 - ₹102.00000
- Issue Size: 345600 - 500000
- Min Bid Qty: 2400
- Open Date: 2026-08-24
- Close Date: 2026-08-27
How might the heavy reliance on QIB subscription (3.45x) versus weak retail interest (0.13x) impact the stock's listing price and early trading volatility?
Given the 100% revenue concentration in a single Tier 3 city hospital, what specific expansion strategies are outlined to mitigate geographic risk post-IPO?
How will the allocation of ₹17 crores for debt repayment affect the company's high debt-to-equity ratio of 3.20, and what is the projected timeline for achieving a healthier leverage profile?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
